CHAT and early-onset autosomal dominant Alzheimer disease: Treatment with naringenin increases ChAT in the hippocampus in a rat model of Alzheimer’s disease- (AD-) type neurodegeneration with cognitive impairment (ADTNDCI), with a concomitant decrease in the loss of ChAT positive neurons and impairments in spatial learning and memory [37].